ChromaDex Corp (NAGE): Company Short-Term Debts

Public company logo of niagenbioscience.com (NAGE)

Chromadex Corp (NAGE) operates in a neutral geopolitical environment, remaining fully insulated from trade conflicts and sanctions. The company generates revenue by supplying unique components for cosmetics and dietary supplements that support cellular energy. The company's price chart with the 0.00 indicator complements data regarding the proficient management of Chromadex Corp, which effectively protects patents and expands the B2B sector.

NAGE (ChromaDex Corporation) Company Short-Term Debts history from 03/20/2025 to 10/30/2026

Analytical breakdowns for ChromaDex (NAGE)

- stock price and consensus target price:
Stock Price Chromadex Corp|NAGE - Analyst Median Target
- stock exchange capitalization data:
Market Capitalization ChromaDex Corp.|NAGE - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share ChromaDex|NAGE - Book Capitalization|Market Value to Book Value Ratio niagenbioscience.com|NAGE - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Chromadex Corp|NAGE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital ChromaDex Corp.|NAGE - Company Total Debt Obligations|Debt to Book Capitalization Ratio ChromaDex Corp.|NAGE - Company Long-Term Indebtedness|Company Short-Term Debt ChromaDex|Quick Liquidity Indicator niagenbioscience.com
- net income and valuation multiples indicators:
NAGE - Profit After Payment of Taxes
Fundamental company analysis:NAGE - Niagen
Flagship merchandise of ChromaDex

Asset quality assessment begins with an analysis of liquidity and the company's ability to service current liabilities. This metric measures the aggregate of loans maturing within one year, revealing the business's dependence on rapid external financing. The trend in short-term debt volume signals potential cash flow gaps. For Chromadex Corp (NAGE), an increase in this indicator may suggest a shortage of funds to cover patent disputes, creating capitalization risks if B2B supply margins decline.

Direct competitors

Intuitive - Company Short-Term Debts|Short-Term Debt Volume Danaher Corporation DHR|BDX: Company Short-Term Debts|Company Current Liabilities STERIS Group|WST (West Pharmaceutical Services) - Company Short-Term Debts|Company Short-Term Debts baxter.com|Company Short-Term Debt Masimo (MASI)|Company Short-Term Debt STVN (Stevanato Group SpA)|Teleflex Inc - Company Current Liabilities|Company Short-Term Loans and Borrowings MMSI|Envista Holdings - Company Short-Term Debts|Short-Term Debt Volume icumed.com ICUI|Dentsply Sirona (XRAY) - Company Short-Term Debt|Company Short-Term Indebtedness LMAT|Company Short-Term Debt AtriCure Corp|STAAR Surgical Co (STAA) - Short-Term Debt Volume|Company Current Liabilities ZIMV (ZimVie Inc.)|Amount of Current Liabilities ANGO|Company Short-Term Debt Cerus CERS|Company Short-Term Loans and Borrowings TKNO|MGRM: Company Current Liabilities|STSS - Company Short-Term Debts|infusystem.com (INFU) - Company Short-Term Debt|Company Current Liabilities utahmed.com|KRMD (KORU Medical Systems, Inc.) - Company Short-Term Debts|Short-Term Debt Nyxoah SA NYXH|Company Short-Term Debt Microbot Medical Inc (MBOT)|Pro-Dex Inc. - Company Short-Term Indebtedness|Zentek Ltd. - Company Current Liabilities|Amount of Current Liabilities ELUT (elutia.com)|MLSS - Company Short-Term Debt|Short-Term Debt Volume NEXGEL Inc. NXGL|RVP: Company Short-Term Debts|Company Current Liabilities Harvard Bioscience Inc.|FEMY (Femasys Inc.) - Company Short-Term Debts|MHUA: Company Short-Term Loans and Borrowings|Company Short-Term Debt Predictive Oncology (POAI)|CJMB (callanjmb.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Atrion Corp ATRI|NeuroMetrix Corporation (NURO) - Short-Term Debt